| Details |
title |
year |
| Details |
P3.13-06 ANALYSIS OF ALK REARRANGEMENT NON-SMALL CELL LUNG CANCER CELL BLO... |
2018 |
| Details |
OA12.03 ACTIVITY OF CRIZOTINIB IN MET OR ROS1 POSITIVE (+) NSCLC: RESULTS ... |
2018 |
| Details |
P1.12-16 MANAGEMENT OF ELDERLY SMALL-CELL LUNG CANCER PATIENTS IN A ROMANI... |
2018 |
| Details |
P1.01-52 BR-34- RANDOMIZED TRIAL OF DURVALUMAB & TREMELIMUMAB +/- PLATINUM... |
2018 |
| Details |
MA16.04 CLINICAL AND MOLECULAR CHARACTERISTICS OF EGFR MUTANT LUNG CANCERS... |
2018 |
| Details |
P3.01-007 HETEROGENEOUS RESISTANCE MECHANISMS IN REBIOPSIES FROM EGFR-MUTA... |
2017 |
| Details |
P1.02-034 NON-INVASIVE QUALITATIVE DIAGNOSIS OF LUNG CANCER ENABLED BY SPE... |
2017 |
| Details |
MA 07.07 CLINICAL OUTCOMES AND ALK RESISTANCE MUTATIONS IN ALK+ NON-SMALL ... |
2017 |
| Details |
MA 03.01 NAB-PACLITAXEL ± CC-486 AS SECOND-LINE TREATMENT OF ADVANCED NSC... |
2017 |
| Details |
MA 11.03 GEFITINIB AS FIRST-LINE TREATMENT OF PLASMA CTDNA EGFR MUTATION-P... |
2017 |
| Details |
P2.05-021 OCCULT NODAL METASTASIS FOLLOWING LOBECTOMY FOR CLINICAL STAGE I... |
2017 |
| Details |
P1.03-023 THE REAL-WORLD PRACTICE OF BEVACIZUMAB PLUS CHEMOTHERAPY IN STAG... |
2017 |
| Details |
MA 07.07 CLINICAL OUTCOMES AND ALK RESISTANCE MUTATIONS IN ALK+ NON-SMALL ... |
2017 |
| Details |
P2.07-012 PATTERNS OF RESPONSE TO NIVOLUMAB IN PATIENTS WITH NON-SMALL CEL... |
2017 |
| Details |
P2.07-027 EFFICACY AND SAFETY OF NIVOLUMAB THERAPY FOR ADVANCED NSCLC IN T... |
2017 |
| Details |
P2.01-028 CLINICAL CORRELATION BETWEEN CTCS ENUMERATION BASED ON NEW DETEC... |
2017 |
| Details |
OA 04.06 SURGEON PRACTICES FOR POST RESECTION LUNG CANCER SURVEILLANCE: CO... |
2017 |
| Details |
P1.06-002 THE ROLE OF COMORBIDITY IN THE MANAGEMENT AND PROGNOSIS IN NONSM... |
2017 |
| Details |
P1.01-002 TP53 MUTATIONS PREDICT FOR POOR SURVIVAL IN ALK REARRANGEMENT LU... |
2017 |
| Details |
OA 02.05 RESPECT-MESO: AN INTERNATIONAL RANDOMISED CONTROLLED TRIAL TO ASS... |
2017 |